Jia Zhu

Dr. Jia Zhu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FSFei fei Sun
Fei fei Sun
JZJia Zhu
Jia Zhu
SLSuying Lu
Suying Lu
ZZZijun Zhen
Zijun Zhen
JWJuan Wang
Juan Wang
XSXiaofei Sun
Xiaofei Sun
Systemic inflammatory parameters are associated with poor outcomes in malignant patients. Several inflammation-based cumulative prognostic score systems were established for various solid tumors. However, there is few inflammation based cumulative prognostic score system for patients with diffuse large B cell lymphoma (DLBCL). We retrospectively reviewed 564 adult DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) therapy between Nov 1 2006 and Dec 30 2013 and assessed the prognostic significance of six systemic inflammatory parameters evaluated in previous studies by univariate and multivariate analysis:C-reactive protein(CRP), albumin levels, the lymphocyte-monocyte ratio (LMR), the neutrophil-lymphocyte ratio(NLR), the platelet-lymphocyte ratio(PLR)and fibrinogen levels. Multivariate analysis identified CRP, albumin levels and the LMR are three independent prognostic parameters for overall survival (OS). Based on these three factors, we constructed a novel inflammation-based cumulative prognostic score (ICPS) system. Four risk groups were formed: group ICPS = 0, ICPS = 1, ICPS = 2 and ICPS = 3. Advanced multivariate analysis indicated that the ICPS model is a prognostic score system independent of International Prognostic Index (IPI) for both progression-free survival (PFS) (p < 0.001) and OS (p < 0.001). The 3-year OS for patients with ICPS =0, ICPS =1, ICPS =2 and ICPS =3 were 95.6, 88.2, 76.0 and 62.2%, respectively (p < 0.001). The 3-year PFS for patients with ICPS = 0–1, ICPS = 2 and ICPS = 3 were 84.8, 71.6 and 54.5%, respectively (p < 0.001). The prognostic value of the ICPS model indicated that the degree of systemic inflammatory status was associated with clinical outcomes of patients with DLBCL in rituximab era. The ICPS model was shown to classify risk groups more accurately than any single inflammatory prognostic parameters. These findings may be useful for identifying candidates for further inflammation-related mechanism research or novel anti-inflammation target therapies.

14 September 2015 in Chinese Journal of Cancer
Verified
Journal Article
Open access
PDF file
JZJia Zhu
Jia Zhu
JWJuan Wang
Juan Wang
ZZZijun Zhen
Zijun Zhen
SLSu-Ying Lu
Su-Ying Lu
FZFei Zhang
Fei Zhang
XSXiaofei Sun
Xiaofei Sun
Brain metastasis is common in relapsed neuroblastoma patients, but the characteristics of brain metastasis remain largely unknown. This study aimed to investigate the status of brain metastasis with neuroblastoma in South China. In this retrospective case-based study, 106 patients with stage 4 neuroblastoma from the Department of Pediatric Oncology in Sun Yat-sen University Cancer Center between January 2004 and May 2013 were included. The incidence, risk factors, and survival status of these patients were reviewed and analyzed. Of the 106 patients, 11 (10.4%) developed brain metastasis, accounting for 20.0% of 55 patients with relapse or progression. The age at initial diagnosis of the 11 patients ranged from 2 to 10 years (median 4 years), which was younger than that of the patients without brain metastasis (median 5 years, range 1–10 years, P = 0.073). The male to female ratio of the 11 patients was 8:3, which was not significantly different from that of the patients without brain metastasis (P = 0.86). Patients with brain metastasis had higher lactate dehydrogenase levels than those without brain metastasis, but the differences were not significant (P = 0.076). Eight patients died, and 3 patients survived. The median interval from the initial diagnosis to the development of brain metastasis was 18 months (range 6–32 months). The median survival was 4 months (range 1 day to 29 months) after the diagnosis of brain metastasis. The median interval from the manifestation of brain metastasis to death was 3 months (range 1 day to 11 months). High-risk factors for brain metastasis in cases of neuroblastoma include bone marrow involvement and a younger age at initial diagnosis. Nevertheless, multiple treatment modalities can improve disease-free survival.

10 February 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
HCHuimou Chen
Huimou Chen
MLMengzhen Li
Mengzhen Li
YZYu Zhang
Yu Zhang
MSMengjia Song
Mengjia Song
YQYi Que
Yi Que
YZYi-zhuo Zhang
Yi-zhuo Zhang
Rhabdomyosarcoma (RMS) is one of the most common solid tumors in children and adolescents. Patients with relapsed/refractory RMS have limited treatment options, highlighting the urgency for the identification of novel therapeutic targets for RMS. In the present study, aurora kinase B (AURKB) was found to be highly expressed in RMS and associated with unfavorable prognosis of patients. Functional experiments indicated that inhibition of AURKB significantly reduced RMS cell proliferation, induced apoptosis and ferroptosis, and suppressed RMS growth in vivo. The highly expressed AURKB in RMS contributes to the apoptosis and ferroptosis resistance of tumor cells through the nucleophosmin 1 (NPM1)/Sp1 transcription factor (SP1)/acyl-CoA synthetase long-chain family member 5 (ACSL5) axis. Furthermore, inhibition of AURKB exerted an anti-RMS effect together with vincristine both in vitro and in vivo, with tolerable toxicity. The above findings provide insights we believe are new into the tumorigenesis of RMS, especially with regard to apoptosis or ferroptosis resistance, indicating that AURKB may be a potential target for clinical intervention in patients with RMS.

23 May 2025 in eClinicalMedicine
Verified
Journal Article
Open access
SLSuying Lu
Suying Lu
YQYi Que
Yi Que
DLDongyang Liu
Dongyang Liu
FSFeifei Sun
Feifei Sun
XYXueting Yao
Xueting Yao
YZYi-zhuo Zhang
Yi-zhuo Zhang
Anlotinib is a novel highly potent multitargeted tyrosine kinase inhibitor. However, the safety, recommended dosage, pharmacokinetics (PK) characteristics, and efficacy of anlotinib in paediatric patients have not been fully studied. We aimed to evaluate the safety, PK, and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas. This was an open-label, single-centre, single-arm, phase I study utilizing a “3 + 3” design. Participants were recruited at the Sun Yat-sen University Cancer Centre in China. Paediatric patients aged 5–18 years with a diagnosis of high-risk, relapsed, or refractory sarcomas were eligible for enrolment in this study. Anlotinib was administered orally once daily on a 2-week-on/1-week-off schedule. Treatment continued until disease progression, death, unacceptable toxicity, or withdrawal of consent for any reason. For patients receiving anlotinib as maintenance therapy, the maximum treatment duration was one year. The primary endpoint of phase Ia was the maximum tolerated dose (MTD) of anlotinib. The primary endpoint of phase Ib was the recommended phase II dose (RP2D) of anlotinib. Secondary endpoints included safety, PK, and efficacy. Efficacy endpoints, such as objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), were assessed at every 2 cycles for patients with measurable lesions until disease progression or intolerable toxicity. Patients with a complete response (CR) at baseline were assessed every 4 cycles until disease progression, or intolerable toxicity, or upon completion of one year of treatment. The primary analysis included all participants who received at least one dose of anlotinib, following the per protocol approach. The safety analysis included all participants who received at least one dose of anlotinib and were monitored for adverse events during the treatment period. This study is registered with ClinicalTrials.gov, NCT04659733. Between December 29, 2020, and September 7, 2022, 34 patients were enrolled for toxicity. Among them, 61.8% (21/34) patients were evaluable for efficacy, and 38.2% (13/34) received anlotinib as maintenance therapy. Two patients (5.9%) experienced dose-limiting toxicities, including grade 3 hematuria and grade 3 hand-foot syndrome. AEs were reported in all patients, with most being grade 1 or 2 in severity. The most common AEs of any grade were hypothyroidism (58.8%, 20/34), diarrhoea (41.2%, 14/34) and abdominal pain (38.2%, 13/34). No grade 4 or treatment-related deaths occurred. PK analysis indicated a significant correlation between abdominal pain and higher steady-state trough concentrations [OR 1.08 (95% CI: 1.01–1.17), P = 0.04] as well as AUCτ [OR 1.00 (95% CI: 1.00–1.01), P = 0.04]. The MTD and RP2D of anlotinib for paediatric patients (5–18 years) was 8 mg for those under 35 kg and 12 mg for those 35 kg or more. The ORR and DCR for evaluable patients were 0% (95% CI: 0%–0%) and 52.4% (95% CI: 29.1%–75.7%), respectively. The 2-year PFS and OS rates for patients who received anlotinib as maintenance therapy were 84.6% (95% CI: 51.2%–95.9%) and 92.3% (95% CI: 56.6%–98.9%), respectively. Anlotinib was well tolerated in paediatric patients. Our findings provide preliminary evidence of the efficacy of anlotinib as a maintenance therapy in paediatric patients with high risk, relapsed/refractory sarcoma who achieved a CR. Further investigation of anlotinib in larger, controlled studies is needed to determine its clinical utility. The 10.13039/501100012166 National Key Research and Development Program of China , the National Science and Technology Major Projects, the 10.13039/501100001809 National Natural Science Foundation of China , the Young Science and Technology Talent Support Program of Guangdong Precision Medicine Application Association, and Capital’s Funds for Health Improvement and Research.

5 June 2025 in Holistic Integrative Oncology
Verified
Journal Article
Open access
PDF file
YLYingxia Lan
Yingxia Lan
ZXZizheng Xiao
Zizheng Xiao
YQYi Que
Yi Que
YWYi Wang
Yi Wang
YHYe Hong
Ye Hong
YZYi-zhuo Zhang
Yi-zhuo Zhang
Purpose: Pediatric lymphoma patients generally demonstrate a favorable long-term survival rate. The use of anti-programmed death-1 (PD-1) monoclonal antibodies has significantly improved the response rates in adult patients with refractory/relapsed lymphoma, particularly those with Hodgkin lymphoma and NK/T cell lymphoma. This study aimed to evaluate the real-world efficacy and safety of PD-1 antibody monotherapy or combination therapy in pediatric lymphoma patients. Methods: From March 1, 2017, to October 25, 2022, we retrospectively analyzed data from 41 pediatric lymphoma patients who received PD-1 antibody treatment, including those with Hodgkin lymphoma, extranodal NK/T cell lymphoma, primary mediastinal large B-cell lymphoma, and other subtypes. Kaplan–Meier analysis was used to estimate progression-free survival (PFS) and overall survival (OS). Descriptive statistics were used to report response rates and adverse effects. Results: The median follow-up period was 22.4 months (range, 1.3–67.6 months), and the overall response rate for the entire cohort was 82.9% (51.2% complete response [CR], 31.7% partial response [PR]). Only two patients died due to disease progression. The two-year PFS rate was 63.0 ± 8.5%, and the median OS and PFS were not reached. PD-1 antibodies were generally well tolerated, particularly in patients receiving monotherapy. Conclusion: Our findings suggest that PD-1 antibody treatment offers a high response rate and low toxicity in pediatric lymphoma patients.

27 January 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Open access
JZJia Zhu
Jia Zhu
HCHuadong Chen
Huadong Chen
TCTingting Chen
Tingting Chen
ZZZijun Zhen
Zijun Zhen
JWJuan Wang
Juan Wang
XSXiaofei Sun
Xiaofei Sun
The aim of the study was to explore the clinicopathologic characteristics of sacrococcygeal yolk sac tumor (SYST) associated with relapse and the role of sensitivity to neoadjuvant chemotherapy in predicting outcome. The authors investigated prognostic factors of age, stage, initial tumor size, pathologic response to neoadjuvant chemotherapy, and alfa fetoprotein. A total of 26 patients with SYST were enrolled. Neoadjuvant chemotherapy was administered to 20 cases. Six patients underwent resection as initial therapy. Recurrence occurred in 12 patients. Nine patients with specimens exhibiting no malignant component after chemotherapy did not experience recurrence. By contrast, relapses occurred in 7 of 11 patients with viable residual tumor after neoadjuvant chemotherapy. All relapsed patients still achieved partial remission or complete remission after salvage therapy. Five-year relapse-free survival and overall survival rates were 55.2% and 100%, respectively (median follow-up, 59.5 mo; range, 16 to 155). Patients with complete necrosis after neoadjuvant chemotherapy had a better outcome compared with children with viable residual tumor. Relapse-free survival of pediatric SYSTs in this cohort were still low and warrants the multidisciplinary effort.